Royalty Pharma plc Files 8-K: Material Agreement & Financial Obligations
Ticker: RPRX · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $500 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, 8-k
TL;DR
Royalty Pharma just signed a big deal and took on new financial obligations, filing an 8-K today.
AI Summary
On June 10, 2024, Royalty Pharma plc entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. Financial statements and exhibits are included as part of this report.
Why It Matters
This 8-K filing signals a significant new agreement and potential financial commitments for Royalty Pharma plc, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and new financial obligations, which inherently carry some level of risk and require further investigation into the specifics of the agreement.
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- June 10, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Royalty Pharma plc?
The filing does not specify the details of the material definitive agreement, only that one was entered into on June 10, 2024.
What are the specific financial obligations created by this filing?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but does not provide specific details or amounts.
Are there any new financial statements included with this 8-K filing?
Yes, the filing indicates that Financial Statements and Exhibits are included.
What is Royalty Pharma plc's principal executive office address?
The principal executive offices are located at 110 East 59th Street, New York, New York 10022.
What is the Commission File Number for Royalty Pharma plc?
The Commission File Number for Royalty Pharma plc is 001-39329.
Filing Stats: 964 words · 4 min read · ~3 pages · Grade level 8.7 · Accepted 2024-06-10 16:58:32
Key Financial Figures
- $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
- $500 million — ed its previously announced offering of $500 million aggregate principal amount of 5.150% Se
Filing Documents
- d851509d8k.htm (8-K) — 28KB
- d851509dex42.htm (EX-4.2) — 176KB
- d851509dex51.htm (EX-5.1) — 12KB
- d851509dex52.htm (EX-5.2) — 66KB
- g851509g0610231735024.jpg (GRAPHIC) — 2KB
- 0001193125-24-158417.txt ( ) — 458KB
- rprx-20240610.xsd (EX-101.SCH) — 3KB
- rprx-20240610_lab.xml (EX-101.LAB) — 17KB
- rprx-20240610_pre.xml (EX-101.PRE) — 11KB
- d851509d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 10, 2024 ROYALTY PHARMA PLC By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer